Metformin

Researchers recently reported that adults who skip breakfast are more likely to develop CVD and are at greater risk for mortality compared to those who never skip the meal — one of the top stories in endocrinology last week.

The FDA-approved liquid formulation of extended-release metformin is now available in the United States for patients who cannot swallow solid medications. It was the top story in endocrinology last week.

Chinese adults with type 1 diabetes can avoid insulin-related weight gain and use less insulin by adding metformin to treatment regimens, according to findings published in the Journal of Diabetes.

Adults with inflammatory disease prescribed glucocorticoid therapy experienced an improvement in several metabolic parameters after adding metformin therapy for 12 weeks compared with similar adults assigned placebo, according to findings from a phase 2 study published in The Lancet Diabetes & Endocrinology.

The only FDA-approved liquid formulation of extended-release metformin is now available in the United States, according to a press release from Sun Pharma.

Use of statins as monotherapy or in combination with metformin appeared associated with lower mortality among men with high-risk prostate cancer, according to results of a retrospective study published in Cancer Medicine.

A population-based, retrospective cohort study showed an association between metformin and a lower risk for age-related macular degeneration.

Adding liraglutide to metformin may help reduce the risk for developing type 2 diabetes vs. metformin alone for women with gestational diabetes, according to findings published in the Journal of Diabetes and its Complications.

FDA-approved metformin products do not contain dangerous levels of nitrosodimethylamine, or NDMA, according to laboratory results released by the FDA.

The FDA on Monday approved the first oral therapy to combine three type 2 diabetes medications into one pill: the SGLT2 inhibitor empagliflozin, the DPP-IV inhibitor linagliptin and metformin hydrochloride extended release, according to a press release from Boehringer Ingelheim and Eli Lilly and Co.